SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3489-3495. Prepublished online as a Blood First Edition Paper on January 5, 2007; DOI 10.1182/blood-2006-08-040410. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-08-040410v1 109/8/3489    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Avet-Loiseau, H. Articles by Mathiot, C. Search for Related Content PubMed PubMed Citation Articles by Avet-Loiseau, H. Articles by Mathiot, C. Related Collections Oncogenes and Tumor Suppressors Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome Hervé Avet-Loiseau1,2, Michel Attal3, Philippe Moreau1,4, Catherine Charbonnel1,2, Frédéric Garban5, Cyrille Hulin6, Serge Leyvraz7, Mauricette Michallet8, Ibrahim Yakoub-Agha9, Laurent Garderet10, Gérald Marit11, Lucienne Michaux12, Laurent Voillat13, Marc Renaud14, Bernard Grosbois15, Gaelle Guillerm16, Lotfi Benboubker17, Mathieu Monconduit18, Catherine Thieblemont19, Philippe Casassus20, Denis Caillot21, Anne-Marie Stoppa22, Jean-Jacques Sotto5, Marc Wetterwald23, Charles Dumontet8, Jean-Gabriel Fuzibet24, Isabelle Azais25, Véronique Dorvaux26, Marc Zandecki27, Régis Bataille1, Stéphane Minvielle1,2, Jean-Luc Harousseau4, Thierry Facon9, and Claire Mathiot28 1 Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 601, Nantes, France; 2 Hematology Laboratory, University Hospital Hôtel-Dieu, Nantes, France; 3 Hematology Department, University Hospital Purpan, Toulouse, France; 4 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France; 5 Hematology Department, University Hospital Michalon, Grenoble, France; 6 Hematology Department, University Hospital Brabois, Nancy, France; 7 Hematology Department, University Hospital, Lausanne, Switzerland, for the Swiss Group for Clinical Cancer Research (SAKK); 8 Hematology Department, University Hospital Edouard Herriot, Lyon, France; 9 Hematology Department, University Hospital Huriez, Lille, France; 10 Hematology Department, University Hospital Saint-Antoine, Paris, France; 11 Hematology Department, University Hospital Haut-Lévêque, Bordeaux, France; 12 Hematology Department, University Hospital, Haine, Belgium; 13 Hematology Department, University Hospital Minjoz, Besançon, France; 14 Hematology Department, University Hospital Jean Bernard, Poitiers, France; 15 Internal Medicine Department, University Hospital Sud, Rennes, France; 16 Hematology Department, University Hospital Morvan, Brest, France; 17 Hematology Department, University Hospital Bretonneau, Tours, France; 18 Hematology Department, Becquerel Cancer Center, Rouen, France; 19 Hematology Department, University Hospital, Pierre-Bénite, France; 20 Hematology Department, University Hospital Avicenne, Bobigny, France; 21 Hematology Department, University Hospital, Dijon, France; 22 Hematology Department, Paoli Calmette Cancer Center, Marseille, France; 23 Hematology Department, Hospital, Dunkerque, France; 24 Internal Medicine Department, University Hospital L'Archet 1, Nice, France; 25 Rheumatology Department, University Hospital Jean Bernard, Poitiers, France; 26 Hematology Department, Hospital Nôtre-Dame de Bon Secours, Metz, France; 27 Hematology Laboratory, University Hospital Larrey, Angers, France; 28 Hematology Department, Curie Cancer Center, Paris, France Acquired genomic aberrations have been shown to significantly impact survival in several hematologic malignancies. We analyzed the prognostic value of the most frequent chromosomal changes in a large series of patients with newly diagnosed symptomatic myeloma prospectively enrolled in homogeneous therapeutic trials. All the 1064 patients enrolled in the IFM99 trials conducted by the Intergroupe Francophone du Myélome benefited from an interphase fluorescence in situ hybridization analysis performed on purified bone marrow plasma cells. They were systematically screened for the following genomic aberrations: del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p). Chromosomal changes were observed in 90% of the patients. The del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p) were present in 48%, 21%, 14%, 39%, 13%, and 11% of the patients, respectively. After a median follow-up of 41 months, univariate statistical analyses revealed that del(13), t(4;14), nonhyperdiploidy, and del(17p) negatively impacted both the event-free survival and the overall survival, whereas t(11;14) and MYC translocations did not influence the prognosis. Multivariate analyses on 513 patients annotated for all the parameters showed that only t(4;14) and del(17p) retained prognostic value for both the event-free and overall survivals. When compared with the currently used International Staging System, this prognostic model compares favorably. In myeloma, the genomic aberrations t(4;14) and del(17p), together with ß2-microglobulin level, are important independent predictors of survival. These findings have implications for the design of risk-adapted treatment strategies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Multiple myeloma and FISH (but no CHIPS) Rafael Fonseca Blood 2007 109: 3132-3133. [Full Text] [PDF] This article has been cited by other articles: J Yeung and H Chang Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836. [Abstract] [Full Text] [PDF] J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766. [Abstract] [Full Text] [PDF] T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability Blood, May 1, 2008; 111(9): 4700 - 4705. [Abstract] [Full Text] [PDF] J.-P. Fermand Initial Therapy for Multiple Myeloma: Role of Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 375 - 379. [Abstract] [Full Text] [PDF] A. K. Stewart A Risk-adapted Approach to Myeloma Therapy ASCO Educational Book, January 1, 2008; 2008(1): 380 - 384. [Abstract] [Full Text] [PDF] K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications Clin. Cancer Res., December 15, 2007; 13(24): 7289 - 7295. [Abstract] [Full Text] [PDF] M. W. Jenner, P. E. Leone, B. A. Walker, F. M. Ross, D. C. Johnson, D. Gonzalez, L. Chiecchio, E. Dachs Cabanas, G. Paolo Dagrada, M. Nightingale, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma Blood, November 1, 2007; 110(9): 3291 - 3300. [Abstract] [Full Text] [PDF] D. Gonzalez, M. van der Burg, R. Garcia-Sanz, J. A. Fenton, A. W. Langerak, M. Gonzalez, J. J. M. van Dongen, J. F. San Miguel, and G. J. Morgan Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma Blood, November 1, 2007; 110(9): 3112 - 3121. [Abstract] [Full Text] [PDF] FISHing for Risk Profiles in Multiple Myeloma Journal Watch Oncology and Hematology, May 7, 2007; 2007(507): 2 - 2. [Full Text] R. Fonseca Strategies for Risk-Adapted Therapy in Myeloma Hematology, January 1, 2007; 2007(1): 304 - 310. [Abstract] [Full Text] [PDF] M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau Stem Cell Transplantation in Multiple Myeloma Hematology, January 1, 2007; 2007(1): 311 - 316. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020